|
Aug 21
|
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
|
|
Aug 16
|
With 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investors
|
|
Aug 5
|
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
|
|
May 10
|
Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review
|
|
May 8
|
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
|
|
May 7
|
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
|
|
Mar 27
|
Independent Director of Design Therapeutics Picks Up 88% More Stock
|
|
Mar 23
|
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
|
|
Mar 20
|
Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript
|
|
Mar 20
|
Q4 2023 Design Therapeutics Inc Earnings Call
|
|
Mar 19
|
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 12
|
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
|
|
Dec 18
|
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know
|